Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.94 USD | +0.45% | +2.16% | -12.41% |
May. 10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
May. 10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
ETFs positioned on Bristol-Myers Squibb Company
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.97% | 0 M€ | +12.39% | - | |
4.99% | 2 M€ | -.--% | ||
4.01% | 0 M€ | +7.69% | - | |
2.63% | 0 M€ | +12.21% | - | |
2.37% | 2 M€ | -25.75% | ||
2.29% | 0 M€ | +1.08% | - | |
2.08% | 9 M€ | -.--% | - | |
1.90% | 16 M€ | -3.37% | ||
1.85% | 0 M€ | +9.27% | ||
1.43% | 5 M€ | -72.95% | - | |
1.42% | 9 M€ | -4.31% | - | |
1.37% | 26 M€ | +16.85% | - | |
1.26% | 0 M€ | +5.32% | ||
1.00% | 0 M€ | +0.69% | ||
0.99% | 0 M€ | +8.67% | ||
0.83% | 0 M€ | +8.99% | ||
0.82% | 0 M€ | +4.88% | ||
0.80% | 0 M€ | +12.85% | ||
0.78% | 3 M€ | +15.16% | - | |
0.78% | 13 M€ | -.--% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.41% | 91.1B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
-2.71% | 159B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company